Keith R. Hummel is a member of tCravath's Litigation Department and Co‑Chair of the Intellectual Property Practice. He has extensive experience litigating complex commercial, intellectual property and antitrust disputes for plaintiffs and defendants in diverse fields, including biotechnology, pharmaceuticals, medical devices, home automation, computer hardware and software, telecommunications, coating systems, and wine and spirits.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2026 Lawdragon 500 Leading Litigators in America | 2026 | IP Litigation |
| The 2025 Lawdragon 500 Leading Litigators in America | 2025 | IP Litigation |
| The 2025 Lawdragon 500 Leading Global Litigators | 2025 | International Litigation & Disputes |
| The 2025 Lawdragon 500 Leading Global Antitrust & Competition Lawyers | 2025 | Complex Litigation, Antitrust, IP |
| The Inaugural Lawdragon 500 Leading Global IP Lawyers | 2025 | Litigation, IP |
| The 2024 Lawdragon 500 Leading Litigators in America | 2024 | IP Litigation |
| The 2024 Lawdragon 500 Leading Global Litigators | 2024 | International Litigation & Disputes |
| Lawdragon 500 Leading Global Litigators | 2023 | International Litigation & Disputes |
| The 2022 Lawdragon 500 Leading Lawyers in America | 2022 | IP Litigation |
| The 2019 Lawdragon 500 Leading Lawyers in America | 2019 | IP Litigation |
Hummel has represented Abiomed, a global medical device company that develops groundbreaking cardiovascular products, in two patent infringement matters relating to guidance systems used in the company’s minimally invasive intravascular blood pumps. He previously represented Abiomed as plaintiff in a trade secret and breach of contract action in Massachusetts federal court against Enmodes and its founder alleging Enmodes wrongfully disclosed Abiomed’s confidential information and trade secrets, reaching a settlement after defeating defendants’ motion to dismiss and moving to dismiss the counterclaims against Abiomed, and he secured complete victories for Abiomed in four inter partes review proceedings and one post-grant proceeding against WhiteSwell Medical relating to patents on devices and methods to treat pulmonary edema.
Hummel won a jury verdict for Amgen in a patent infringement case in Delaware federal court against Sanofi and Regeneron relating to Amgen’s patents covering a class of biologic drugs that treat high cholesterol. Hummel also represented Amgen in litigation concerning its introduction of a biosimilar to AbbVie’s biologic drug, Humira®—one of the world’s largest‑selling drugs—in one of the first cases to proceed under the Biologics Price Competition and Innovation Act (BPCIA). Amgen reached a global settlement with AbbVie that enabled Amgen to market the first approved biosimilar to Humira® in the U.S. and Europe.
Hummel has represented Alarm.com in several patent infringement and contractual matters. He recently secured a favorable resolution in multijurisdictional litigation against Vivint, which spanned eight years and concerned over 35 patents for interactive security and home automation technology. Hummel continues to represent Alarm.com on appeal after winning a trial decision in an International Trade Commission (ITC) investigation initiated by Causam Enterprises over electric demand management systems.